A survey shows that drug shortages in the US cause frustration for physicians, often leading to postponed prescriptions.

Topline data were announced from a phase 3b trial evaluating the concomitant use of ixekizumab and tirzepatide in adults with active psoriatic arthritis and obesity.

Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients Ingelheim, Germany– 12 January, 2026 – Boehringer Ingelheim today announced a strategic ...

The 2025 American Society of Hematology (ASH) meeting in December presented a clear message: scientific innovation and ...

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales VYVGART impact continues with approximately 19 ...

Reported $4.15 billion (YoY growth of +90%) in preliminary* full-year 2025 global product net sales, inclusive of $1.29 billion in fourth quarter sales ...

Patterns repeat each year. Early coordination allows healthcare providers to manage demand in a way that protects ...

The 2026 draft class is being touted as one of the strongest in recent memory, with a trio of prospects in Cameron Boozer, AJ ...

Reversing the standard approved dose levels of nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic melanoma led to less ...

With durable responses, encouraging survival outcomes, and evidence that some patients may become eligible for ...

In the Phase III results, Ziihera plus immunotherapy and chemo improved survival outcomes compared to Herceptin plus chemo.